Kiniksa Reports Q4 Revenue of $202.127M, Beating Consensus
Reports Q4 revenue $202.127M, consensus $201.01M. "Kiniksa continued to drive significant advancements across its commercial and clinical portfolio in 2025. The expanding adoption of IL-1alpha & IL-1beta inhibition with ARCALYST as the preferred second-line treatment for recurrent pericarditis helped drive 62% year-over-year ARCALYST sales growth to $677.6 million. We believe substantial opportunity remains for ARCALYST and we expect 2026 sales of between $900 and $920 million," said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. "Within our clinical pipeline, we expanded our leadership in recurrent pericarditis with the initiation of the KPL-387 Phase 2/3 development program, which could provide an important additional treatment option for patients. We also plan to initiate a Phase 1 trial with KPL-1161, an Fc-modified monoclonal antibody IL-1 receptor antagonist by the end of this year. Importantly, Kiniksa has a robust financial profile which supports these efforts and provides the ability to invest in additional value-creating opportunities."
